<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACM</journal-id><journal-title-group><journal-title>Advances in Clinical Medicine</journal-title></journal-title-group><issn pub-type="epub">2161-8712</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACM.2020.105121</article-id><article-id pub-id-type="publisher-id">ACM-35651</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACM20200500000_22966873.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  SLE患者外周血IFN-α、NE及MPO表达水平及意义
  The Expression and Significance of Serum IFN-α, Serum NE and Serum MPO in Patients with Systemic Lupus Erythematosus
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>李</surname><given-names>梦迪</given-names></name><xref ref-type="aff" rid="aff1"><sup>1</sup></xref><xref ref-type="aff" rid="aff2"><sup>2</sup></xref></contrib></contrib-group><aff id="aff1"><label>1</label><addr-line>null</addr-line></aff><aff id="aff2"><label>1</label><addr-line>青岛大学附属医院风湿免疫科，山东 青岛</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>04</month><year>2020</year></pub-date><volume>10</volume><issue>05</issue><fpage>787</fpage><lpage>795</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
  
    目的：检测系统性红斑狼疮(SLE)患者血清干扰素α (IFN-α)、弹性蛋白酶(NE)及髓过氧化物酶(MPO)水平，探讨IFN-α、NE及MPO水平与SLE疾病活动度、血清学指标和临床表现的相关性及IFN-α、中性粒细胞胞外诱捕网(NETs)两者可能存在的关系。方法：采用酶联免疫吸附法(ELISA)测定SLE患者组与健康对照组血清IFN-α、NE及MPO水平，并分析上述指标之间及上述指标与疾病活动度、血清学指标和临床表现的相关性。结果：SLE患者组血清IFN-α、NE、MPO的水平较健康对照组显著增高(p &lt; 0.05)，差异有统计学意义；SLE患者组血清IFN-α、NE、MPO的水平均与系统性红斑狼疮活动指数(SLEDAI)评分呈正相关(p &lt; 0.05)；SLE患者组血清IFN-α水平与血清补体C3、血红蛋白(Hb)呈负相关(p &lt; 0.05)，与红细胞沉降率(ESR)、24 h尿蛋白定量、抗双链DNA抗体(抗ds-DNA抗体)水平呈正相关(p &lt; 0.05)，血清MPO水平与抗dsDNA抗体呈正相关(p &lt; 0.05)；SLE患者组血清IFN-α水平与血液系统、泌尿系统、关节炎、皮疹、光过敏等临床表现呈正相关(p &lt; 0.05)，血清NE水平与皮疹临床表现呈正相关(p &lt; 0.05)；结果显示SLE患者组NE、MPO呈正相关(p &lt; 0.05)，且IFN-α分别与NE、MPO呈正相关(p &lt; 0.05)。结论：SLE患者组血清IFN-α、NE及MPO水平较健康对照组增高且与SLE中SLEDAI评分、部分血清学指标、临床表现相关，提示IFN-α、NETs水平在SLE发病中发挥作用。同时IFN-α分别与NE、MPO均呈正相关，说明IFN-α与NETs在SLE发病机理中可能具有相关性。
    Objective: To investigate the levels of serum interferon α (IFN-α), elastase (NE) and myeloperoxidase (MPO) in patients with systemic lupus erythematosus (SLE), to explore the correlation of IFN-α, NE and MPO levels with disease activity, serological indexes and clinical manifestations of SLE and the possible relationship between IFN-α and neutrophil extracellular traps (NETs). Methods: The levels of serum IFN-α, NE and MPO were measured by Enzyme-linked immunoassay (ELISA) method between SLE patients and healthy controls, to analyze the correlation of IFN-α, NE and MPO levels with disease activity, serological indexes and clinical manifestations in SLE patients. Results: The levels of IFN-α, NE and MPO in the SLE patient group were significantly higher than those in the healthy control group (p &lt; 0.05); the levels of IFN-α, NE, MPO in patients with SLE were positively correlated with systemic lupus erythematosus disease activity index (SLEDAI) score; in patients with SLE, the level of serum IFN-α was negatively correlated with serum complement C3 and Hemoglobin (Hb) (p &lt; 0.05), and positively correlated with erythrocyte sedimentation rate (ESR), 24-hour urinary protein and anti-dsDNA antibody level; the level of serum MPO in patients with SLE was positively correlated with anti-dsDNA antibody (p &lt; 0.05); the level of serum IFN-α in patients with SLE was positively correlated with clinical manifestations such as blood system, urinary system, arthritis, rash, photosensitivity (p &lt; 0.05); the level of serum NE in patients with SLE was positively correlated with the clinical manifestations of rash (p &lt; 0.05). The results showed that NE and MPO in SLE patients were positively correlated (p &lt; 0.05), and IFN-α was positively correlated with NE and MPO respectively (p &lt; 0.05). Conclusion: The serum levels of IFN-α, NE and MPO in patients with SLE were higher than healthy control group and positively correlated with SLEDAI score, serological indexes, clinical manifestations, suggesting that the levels of IFN-α and NETs matter in the pathogenesis of SLE. IFN-α was positively correlated with NE and MPO respectively, indicating that IFN-α and NETs may be related in the pathogenesis of SLE. 
  
 
</p></abstract><kwd-group><kwd>系统性红斑狼疮，干扰素，中性粒细胞胞外诱捕网，相关性分析, Systemic Lupus Erythematosus</kwd><kwd> Interferon</kwd><kwd> Neutrophil Extracellular Traps</kwd><kwd> Correlation Analysis</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>SLE患者外周血IFN-α、NE及MPO表达水平及意义<sup> </sup></title><p>李梦迪</p><p>青岛大学附属医院风湿免疫科，山东 青岛</p><p>收稿日期：2020年5月1日；录用日期：2020年5月13日；发布日期：2020年5月20日</p><disp-formula id="hanspub.35651-formula31"><graphic xlink:href="//html.hanspub.org/file/16-1571315x5_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：检测系统性红斑狼疮(SLE)患者血清干扰素α (IFN-α)、弹性蛋白酶(NE)及髓过氧化物酶(MPO)水平，探讨IFN-α、NE及MPO水平与SLE疾病活动度、血清学指标和临床表现的相关性及IFN-α、中性粒细胞胞外诱捕网(NETs)两者可能存在的关系。方法：采用酶联免疫吸附法(ELISA)测定SLE患者组与健康对照组血清IFN-α、NE及MPO水平，并分析上述指标之间及上述指标与疾病活动度、血清学指标和临床表现的相关性。结果：SLE患者组血清IFN-α、NE、MPO的水平较健康对照组显著增高(p &lt; 0.05)，差异有统计学意义；SLE患者组血清IFN-α、NE、MPO的水平均与系统性红斑狼疮活动指数(SLEDAI)评分呈正相关(p &lt; 0.05)；SLE患者组血清IFN-α水平与血清补体C3、血红蛋白(Hb)呈负相关(p &lt; 0.05)，与红细胞沉降率(ESR)、24 h尿蛋白定量、抗双链DNA抗体(抗ds-DNA抗体)水平呈正相关(p &lt; 0.05)，血清MPO水平与抗dsDNA抗体呈正相关(p &lt; 0.05)；SLE患者组血清IFN-α水平与血液系统、泌尿系统、关节炎、皮疹、光过敏等临床表现呈正相关(p &lt; 0.05)，血清NE水平与皮疹临床表现呈正相关(p &lt; 0.05)；结果显示SLE患者组NE、MPO呈正相关(p &lt; 0.05)，且IFN-α分别与NE、MPO呈正相关(p &lt; 0.05)。结论：SLE患者组血清IFN-α、NE及MPO水平较健康对照组增高且与SLE中SLEDAI评分、部分血清学指标、临床表现相关，提示IFN-α、NETs水平在SLE发病中发挥作用。同时IFN-α分别与NE、MPO均呈正相关，说明IFN-α与NETs在SLE发病机理中可能具有相关性。</p><p>关键词 :系统性红斑狼疮，干扰素，中性粒细胞胞外诱捕网，相关性分析</p><disp-formula id="hanspub.35651-formula32"><graphic xlink:href="//html.hanspub.org/file/16-1571315x6_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2020 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY 4.0).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/16-1571315x7_hanspub.png" /> <img src="//html.hanspub.org/file/16-1571315x8_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>系统性红斑狼疮(systemic lupus erythematosus, SLE)是一种慢性炎症性系统性自身免疫疾病，其特征主要为对核抗原的耐受力下降以及IC (immune complex, IC)在组织中沉积导致炎症。SLE发病机制复杂，涉及免疫系统的多种细胞成分。近来研究发现IFN-α与SLE关系密切，一些用重组人IFN-α治疗病毒性肝炎和血液系统恶性肿瘤的患者发展为SLE，当IFN-α治疗停止时，SLE相关症状通常会改善 [<xref ref-type="bibr" rid="hanspub.35651-ref1">1</xref>]。提示IFN-α可能在SLE发病过程中起重要作用。最近发现中性粒细胞通过形成中性粒细胞胞外诱捕网(neutrophil extracellular traps, NETs)的细胞外结构杀死细菌。该结构主要由组蛋白、DNA和众多蛋白酶组成，其中蛋白酶包括弹性蛋白酶(elastase, NE)和髓过氧化物酶(myeloperoxidase, MPO) [<xref ref-type="bibr" rid="hanspub.35651-ref2">2</xref>]。既往研究表明，与健康对照组相比SLE患者组表现出NETs降解能力的下降。这提示NETs可能与SLE具有相关性，且这种相关性可能是由多种细胞因子介导。本次实验通过检测SLE患者体内IFN-α、MPO、NE水平，分析它们与各临床表现、血清学指标及疾病活动度的相关性等，明确SLE患者体内IFN-α、NETs意义。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选自2019年6月至12月于青岛大学附属医院风湿免疫科住院SLE患者98例。入组患者均符合美国风湿病学会1997年修订的SLE诊断标准，所有纳入患者近期采血前未行大剂量免疫抑制药物及泼尼松等药物治疗。排除标准：其他自身免疫性疾病；冠心病、甲亢、抑郁症，严重感染。健康对照组选自2019年6月至12月于青岛大学附属医院健康查体中心查体者63例。纳入人群无自身免疫相关性疾病、原发性高血压、糖尿病、近期感染及相关遗传疾病家族史，除外妊娠及哺乳期患者。</p><p>收集SLE组与健康对照组的个人信息与临床资料，记录SLE患者的实验室指标，包括血常规、C反应蛋白(C-reactive protein, CRP)、红细胞沉降率(Erythro-cyte sedimentation rate, ESR)、24小时尿蛋白、补体C3、抗可溶性抗原(Extractable nuclear antigen, ENA)抗体谱、抗dsDNA抗体。同时收集明确患者此次入院后的皮肤、关节、神经精神、血液等各系统临床表现以及SLEDAI评分 [<xref ref-type="bibr" rid="hanspub.35651-ref3">3</xref>]。</p><p>本研究方案经本院伦理委员会批准，且所有研究对象均知情同意。</p></sec><sec id="s4_2"><title>2.2. 主要试剂与仪器</title><p>人中性粒细胞弹性蛋白酶酶联免疫吸附测定试剂盒、人干扰素α酶联免疫吸附测定试剂盒购于武汉伊莱瑞特生物公司，人髓过氧化物酶酶联免疫试剂盒购于武汉华美生物工程有限公司。Nano Drop分光光度计、酶标仪来自美国Thermo Fisher公司。</p></sec><sec id="s4_3"><title>2.3. 研究方法</title><p>早5:00采集被研究者空腹静脉血3 ml，在实验室使用离心机以3000转/分离心标本10分钟，用移液器移取离心后的上层血清1 ml装于EP管中，随即编号，将标本保存于−80℃冰箱待用。所有血清避免反复冻融。血清IFN-α、NE、MPO检测均采用ELISA法，具体操作步骤按照试剂盒说明书进行，最后于酶标仪上检测A450 nm吸光值，计算结果。</p></sec><sec id="s4_4"><title>2.4. 统计学方法</title><p>采用SPSS 23.0统计软件进行数据分析，计量资料满足正态分布以(X &#177; S)表示，偏态分布资料以中位数四分位间距[M(QR)]表示，正态分布的计量资料两组间差异性分析用独立样本T检验，不符合正态分布的计量资料差异性分析用秩和检验。两指标相关性分析服从正态分布的进行Pearson相关性分析，不服从正态分布的进行Spearman相关性分析，p &lt; 0.05时差异有统计学意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 一般情况分析及临床特点</title><p>分别收集SLE患者组、健康对照组人群的临床及实验室资料，其中SLE患者98例，男性7例，女性91例，年龄(14~74)岁，平均年龄(36.34 &#177; 14.351)岁；健康对照组63例，男性9例，女性54例，年龄(16~67)岁，平均年龄(39.94 &#177; 11.00)岁。根据被纳入的2组人群结果分析显示他们在性别年龄方面无统计学差异(P &gt; 0.05)。SLE患者临床表现多样，尤以泌尿系统损害为著(SLE患者及健康对照组一般情况见表1)。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Comparison of general conditions between healthy control group and SLE grou</title></caption><table><tbody><thead><tr><th align="center" valign="middle" ></th><th align="center" valign="middle" >健康对照组(n = 63)</th><th align="center" valign="middle" >SLE组(n = 98)</th></tr></thead><tr><td align="center" valign="middle" >年龄(岁)</td><td align="center" valign="middle" >39.94 &#177; 11.00</td><td align="center" valign="middle" >36.34 &#177; 14.351</td></tr><tr><td align="center" valign="middle" >SLEDAI评分</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >14.64 &#177; 6.85</td></tr><tr><td align="center" valign="middle" >Hb (g/L)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >103.28 &#177; 19.34</td></tr><tr><td align="center" valign="middle" >PLT (10<sup>9</sup>/L)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >189.07 &#177; 85.94</td></tr><tr><td align="center" valign="middle" >男/女(例)</td><td align="center" valign="middle" >9/54</td><td align="center" valign="middle" >7/91</td></tr><tr><td align="center" valign="middle" >抗dsDNA抗体(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >45/53</td></tr><tr><td align="center" valign="middle" >抗sm抗体(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >68/30</td></tr><tr><td align="center" valign="middle" >抗核糖核酸蛋白抗体(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >45/53</td></tr><tr><td align="center" valign="middle" >抗核糖体p蛋白抗体(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >68/30</td></tr><tr><td align="center" valign="middle" >神经精神系统(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >91/7</td></tr><tr><td align="center" valign="middle" >血液系统(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >47/51</td></tr><tr><td align="center" valign="middle" >泌尿系统(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >24/74</td></tr><tr><td align="center" valign="middle" >关节炎(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >69/29</td></tr><tr><td align="center" valign="middle" >新发皮疹(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >60/38</td></tr><tr><td align="center" valign="middle" >光过敏(−/+)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >73/25</td></tr><tr><td align="center" valign="middle" >补体C3 (g/l)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.60 (0.42)</td></tr><tr><td align="center" valign="middle" >CRP (mg/l)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >1.01 (10.31)</td></tr><tr><td align="center" valign="middle" >24h尿蛋白(g/L)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >2.01 (2.5)</td></tr><tr><td align="center" valign="middle" >ESR (mm/1h)</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >26 (26.25)</td></tr></tbody></table></table-wrap><p>表1. 健康对照组及SLE组一般情况比较<sup>1</sup></p></sec><sec id="s5_2"><title>3.2. SLE患者组、健康对照组血清中IFN-α、NE及MPO的水平</title><p>ELISA法检测血清中IFN-α、NE及MPO的水平。结果：SLE患者组血清IFN-α、NE、MPO的水平较健康对照组显著增高(p &lt; 0.05)，差异有统计学意义(见表2)。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Levels of IFN-α, NE and MPO in serum of patients with SLE and healthy control</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >分组</th><th align="center" valign="middle" >IFN-α (pg/mL)</th><th align="center" valign="middle" >NE (ng/mL)</th><th align="center" valign="middle" >MPO(ng/ml)</th></tr></thead><tr><td align="center" valign="middle" >健康对照组(n = 63)</td><td align="center" valign="middle" >40.00 (43.73)</td><td align="center" valign="middle" >72.09 (35.78)</td><td align="center" valign="middle" >99.75 (34.58)</td></tr><tr><td align="center" valign="middle" >SLE组(n = 98)</td><td align="center" valign="middle" >93.97 (76.75)<sup>*</sup></td><td align="center" valign="middle" >115.55 (71.26)<sup>*</sup></td><td align="center" valign="middle" >103.56 (42.65)<sup>*</sup></td></tr></tbody></table></table-wrap><p>表2. SLE患者组、健康对照组血清中IFN-α、NE、MPO的水平</p><p><sup>*</sup>表示与健康对照组比较p &lt; 0.05。</p></sec><sec id="s5_3"><title>3.3. SLE患者组血清IFN-α、NE、MPO水平与疾病活动度的关系</title><p>在资料收集时根据SLEDAI评分对98例SLE患者进行评分，并分别分析IFN-α、NE、MPO与SLEDAI评分的相关性。结果表明：SLE患者组血清IFN-α、NE、MPO的水平与SLEDAI呈正相关(r = 0.461, p = 0.000; r = 0.268, p = 0.008; r = 0.203, p = 0.045) (见图1)。</p><p>图1. SLE患者血清IFN-α、NE、MPO与SLEDAI的相关性</p></sec><sec id="s5_4"><title>3.4. SLE患者组IFN-α、NE及MPO水平与血清学指标关系</title><sec id="s5_4_1"><title>3.4.1. SLE患者组IFN-α的水平与血清学指标的关联</title><p>SLE患者血清中IFN-α水平与补体C3、Hb呈现负相关关系(r = −0.204, p = 0.044; r = −0.213, p = 0.035)；与ESR、24 h尿蛋白定量、抗dsDNA抗体水平呈正相关(r = 0.217, p = 0.032; r = 0.262, p = 0.009; r = 0.225, p = 0.026) (见图2)。与CRP、Plt、抗心磷脂抗体、抗核糖核蛋白(ribose nuclear protein, RNP)抗体、抗史密斯(Smith, sm)抗体、抗核糖体p蛋白(ribosomal P protein, rRNP)抗体无关(p &gt; 0.05)。</p></sec><sec id="s5_4_2"><title>3.4.2. SLE患者组NE的水平与血清学指标的关联</title><p>血清NE水平与Hb、24 h尿蛋白定量、抗dsDNA抗体、血清补体C3、ESR、CRP、plt、抗心磷脂抗体、抗RNP抗体、抗sm抗体、抗rRNP抗体无关(p &gt; 0.05)。</p></sec><sec id="s5_4_3"><title>3.4.3. SLE患者组MPO的水平与血清学指标的关联</title><p>血清MPO水平与抗dsDNA抗体呈正相关(r = 0.208, p = 0.04)，与Hb、24 h尿蛋白定量、血清补体C3、ESR、CRP、plt、抗心磷脂抗体、抗RNP抗体、抗sm抗体、抗rRNP抗体无关(p &gt; 0.05)。</p><p>图2. 血清IFN-α水平与血清C3、ESR、Hb、24 h尿蛋白定量相关性分析</p></sec></sec><sec id="s5_5"><title>3.5. SLE患者组血清IFN-α、NE、MPO水平与临床表现的关系</title><sec id="s5_5_1"><title>3.5.1. SLE患者组 IFN-α的水平与临床表现的关联</title><p>血清IFN-α水平与血液系统、泌尿系统、关节炎、皮疹、光过敏等临床表现呈正相关(p &lt; 0.05)，与精神神经系统无关(p &gt; 0.05) (见表3)。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Correlation between IFN-α levels and clinical manifestations in patients with SL</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床表现</th><th align="center" valign="middle"  rowspan="2"  >阳性例数</th><th align="center" valign="middle"  colspan="4"  >IFN-α (pg/mL)</th></tr></thead><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >R值</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >精神神经</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >137.36 (85.12)</td><td align="center" valign="middle" >111.68 (66.08)</td><td align="center" valign="middle" >0.145</td><td align="center" valign="middle" >0.154</td></tr><tr><td align="center" valign="middle" >血液系统</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >98.71 (67.95)</td><td align="center" valign="middle" >82.70 (49.10)</td><td align="center" valign="middle" >0.205</td><td align="center" valign="middle" >0.043*</td></tr><tr><td align="center" valign="middle" >泌尿系统</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >94.66 (75.33)</td><td align="center" valign="middle" >78.36 (38.40)</td><td align="center" valign="middle" >0.237</td><td align="center" valign="middle" >0.019*</td></tr><tr><td align="center" valign="middle" >关节炎</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >97.63 (69.60)</td><td align="center" valign="middle" >84.48 (60.65)</td><td align="center" valign="middle" >0.252</td><td align="center" valign="middle" >0.012*</td></tr><tr><td align="center" valign="middle" >皮疹</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >95.59 (75.91)</td><td align="center" valign="middle" >89.86 (60.15)</td><td align="center" valign="middle" >0.215</td><td align="center" valign="middle" >0.034*</td></tr><tr><td align="center" valign="middle" >光过敏</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >93.16 (45.46)</td><td align="center" valign="middle" >90.61 (70.59)</td><td align="center" valign="middle" >0.235</td><td align="center" valign="middle" >0.020*</td></tr></tbody></table></table-wrap><p>表3. SLE患者IFN-α水平与临床表现的相关性</p><p>注：<sup>*</sup>p &lt; 0.05，有统计学意义。</p></sec><sec id="s5_5_2"><title>3.5.2. SLE患者组NE的水平与临床表现的关联</title><p>血清NE水平与皮疹临床表现呈正相关(p &lt; 0.05)，与血液系统、泌尿系统、关节炎、光过敏、精神神经系统无关(p &gt; 0.05) (见表4)。</p><table-wrap id="table4" ><label><xref ref-type="table" rid="table4">Table 4</xref></label><caption><title> Correlation between NE levels and clinical manifestations in patients with SL</title></caption><table><tbody><thead><tr><th align="center" valign="middle"  rowspan="2"  >临床表现</th><th align="center" valign="middle"  rowspan="2"  >阳性例数</th><th align="center" valign="middle"  colspan="4"  >NE (ng/mL)</th></tr></thead><tr><td align="center" valign="middle" >阳性</td><td align="center" valign="middle" >阴性</td><td align="center" valign="middle" >R值</td><td align="center" valign="middle" >P值</td></tr><tr><td align="center" valign="middle" >精神神经</td><td align="center" valign="middle" >7</td><td align="center" valign="middle" >118.19 (45.13)</td><td align="center" valign="middle" >103.28 (42.86)</td><td align="center" valign="middle" >−0.012</td><td align="center" valign="middle" >0.907</td></tr><tr><td align="center" valign="middle" >血液系统</td><td align="center" valign="middle" >51</td><td align="center" valign="middle" >103.76 (54.10)</td><td align="center" valign="middle" >117.33 (70.67)</td><td align="center" valign="middle" >−0.029</td><td align="center" valign="middle" >0.78</td></tr><tr><td align="center" valign="middle" >泌尿系统</td><td align="center" valign="middle" >74</td><td align="center" valign="middle" >115.55 (61.81)</td><td align="center" valign="middle" >109.11 (76.32)</td><td align="center" valign="middle" >−0.047</td><td align="center" valign="middle" >0.646</td></tr><tr><td align="center" valign="middle" >关节炎</td><td align="center" valign="middle" >29</td><td align="center" valign="middle" >115.32 (59.22)</td><td align="center" valign="middle" >114.60 (64.45)</td><td align="center" valign="middle" >0.04</td><td align="center" valign="middle" >0.696</td></tr><tr><td align="center" valign="middle" >皮疹</td><td align="center" valign="middle" >38</td><td align="center" valign="middle" >121.14 (66.17)</td><td align="center" valign="middle" >104.84 (67.39)</td><td align="center" valign="middle" >0.279</td><td align="center" valign="middle" >0.005*</td></tr><tr><td align="center" valign="middle" >光过敏</td><td align="center" valign="middle" >25</td><td align="center" valign="middle" >118.88 (45.11)</td><td align="center" valign="middle" >103.89 (72.71)</td><td align="center" valign="middle" >0.149</td><td align="center" valign="middle" >0.144</td></tr></tbody></table></table-wrap><p>表4. SLE患者NE水平与临床表现的相关性</p><p>注：<sup>*</sup>p &lt; 0.05，有统计学意义。</p></sec><sec id="s5_5_3"><title>3.5.3. SLE患者组MPO的水平与临床表现的关联</title><p>血清MPO水平与血液系统、泌尿系统、关节炎、光过敏、精神神经系统、皮疹无关(p &gt; 0.05)。</p></sec></sec><sec id="s5_6"><title>3.6. SLE患者组血清IFN-α、NE、MPO水平之间的关联</title><sec id="s5_6_1"><title>3.6.1. SLE患者组血清 NE、MPO水平之间的关联</title><p>SLE患者组血清NE、MPO均可反应NETs水平，统计学显示NE、MPO呈正相关(r = 0.234, p = 0.02) (见图3)，说明两者检测结果反映NETs水平相符。</p></sec><sec id="s5_6_2"><title>3.6.2. SLE患者组血清IFN-α、NE水平之间的关联</title><p>统计学显示SLE患者血清中IFN-α、NE呈正相关(r = 0.245, p = 0.015) (见图3)。</p></sec><sec id="s5_6_3"><title>3.6.3. SLE患者组血清IFN-α、MPO水平之间的关联</title><p>统计学显示SLE患者血清IFN-α、MPO呈正相关(r = 0.273, p = 0.007) (见图3)。</p><p>图3. 血清MPO水平、血清NE水平、血清IFN-α水平关系图</p></sec></sec></sec><sec id="s6"><title>4. 讨论</title><p>SLE是一种以体内产生多种自身抗体为血清学特征、以多组织及多脏器受累为临床特征的经典性自身免疫性疾病。SLE发病机制尚未完全明确，目前普遍认为免疫、遗传、感染、环境、性激素等因素参与其中，免疫因素可能起较大作用，诸多细胞因子也可能参与其中。IFN-α作为I-IFN的重要组分之一，主要具有抗病毒、抗增殖和免疫调节作用。IFN-α主要由pDC产生 [<xref ref-type="bibr" rid="hanspub.35651-ref4">4</xref>]。目前研究发现IFN-α可能参与了多种自身免疫性疾病的发病，如SLE、类风湿关节炎、干燥综合征等。</p><p>本次研究结果显示SLE患者组血清IFN-α的水平较健康对照组显著增高，与既往凌磊 [<xref ref-type="bibr" rid="hanspub.35651-ref5">5</xref>] 等人文献报道是相符合的。提示可能异常增多的IFN-α参与了SLE的发病。IFN-α异常增多的原因众多，推测主要包括I-IFN诱导物持续存在、众多涉及I-IFN产生的遗传因素以及产生I-IFN的多种细胞的异常激活 [<xref ref-type="bibr" rid="hanspub.35651-ref6">6</xref>]。过度激活的I-IFN可能通过不同机制改变免疫功能来实现SLE发病 [<xref ref-type="bibr" rid="hanspub.35651-ref7">7</xref>]，调控T细胞及B细胞等各种免疫细胞的生存、激活及重要功能都被包含在内。本次研究表明SLE病人中IFN-α的血清水平与SLE患者的SLEDAI评分，血液系统、泌尿系统、关节炎、皮疹、光过敏等临床表现以及与抗dsDNA抗体、ESR、24 h尿蛋白定量呈正相关，而与血清补体C3、Hb呈负相关。以上结果均与文献报道相符合。说明IFN-α水平与SLE的疾病活动度及严重程度关系密切，提示血清IFN-α水平的增高可能可以作为一种SLE的临床诊断标准及病情严重程度的判断标准。</p><p>NETs的形成是一种细胞死亡途径，中性粒细胞以网状结构挤压出核物质(如组蛋白、去浓缩染色质和细胞质蛋白)，NETs可以捕获入侵的病原体。NETs在SLE疾病发生、发展过程中发挥着重要作用。本次研究显示SLE患者组血清NE、MPO的水平较健康对照组显著增高，提示NETs在SLE发病过程中起重要作用，与既往蒋秋梅等人 [<xref ref-type="bibr" rid="hanspub.35651-ref8">8</xref>] 研究结果一致。推测NETs在SLE中发病机制可能与体内NETs生成作用增强或与体内NETs降解减弱有关。本次实验显示SLE患者血清NE水平与SLEDAI评分、皮疹表现呈正相关，SLE患者组血清MPO水平与SLEDAI评分、抗dsDNA抗体呈正相关。这一定程度上说明NETs与SLE活动度相关。但此次实验显示NE、MPO与SLE众多器官累及临床表现及部分血清学指标无关，这与Rother [<xref ref-type="bibr" rid="hanspub.35651-ref9">9</xref>] 等人的既往研究结果不符。分析原因不排除样本量太少等原因。</p><p>本次实验结果显示IFN-α与NE、MPO呈正相关，提示外周血NETs水平与血清中IFN-α水平相关。相关机制可能如下：1) SLE患者体内的自身抗体会刺激NETs生成 [<xref ref-type="bibr" rid="hanspub.35651-ref10">10</xref>]。NETs通过产生IFN-α和激活补体系统经典途径和替代途径来促进自身免疫参与发病。2) SLE患者中，NETs的含量能够诱导pDC产生IFN-α [<xref ref-type="bibr" rid="hanspub.35651-ref11">11</xref>]。进而参与SLE病理过程。</p><p>本研究明确与分析了血清IFN-α、MPO、NE水平及其与SLE血清学指标、临床表现以及SLEDAI评分之间的相关性。并且发现NETs与IFN-α之间可能存在某种关系。下一步要从细胞因子的转录表达，具体的信号转导通路等角度出发，进一步探究它们在SLE中的作用及关系。</p></sec><sec id="s7"><title>文章引用</title><p>李梦迪. SLE患者外周血IFN-α、NE及MPO表达水平及意义The Expression and Significance of Serum IFN-α, Serum NE and Serum MPO in Patients with Systemic Lupus Erythematosus[J]. 临床医学进展, 2020, 10(05): 787-795. https://doi.org/10.12677/ACM.2020.105121</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.35651-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">Rönnblom, L.E., Alm, G.V. and Oberg, K.E. (1990) Possible Induction of Systemic Lupus Erythematosus by Interferon-Alpha Treatment in a Patient with a Malignant Carcinoid Tumour. Journal of Internal Medicine, 227, 207-210.  
&lt;br&gt;https://doi.org/10.1111/j.1365-2796.1990.tb00144.x</mixed-citation></ref><ref id="hanspub.35651-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">Brinkmann, V., Reichard, U., Goosmann, C., et al. (2004) Neutrophil Extracellular Traps Kill Bacteria. Science, 303, 1532-1535. &lt;br&gt;https://doi.org/10.1126/science.1092385</mixed-citation></ref><ref id="hanspub.35651-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">中华医学会风湿病学分会. 系统性红斑狼疮诊治指南(草案) [J]. 中华风湿病学杂志, 2003, 7(8): 508-513.</mixed-citation></ref><ref id="hanspub.35651-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Agod, Z., Fekete, T., Budai, M.M., et al. (2017) Regulation of Type I Interferon Responses by Mitochondria-Derived Reactive Oxygen Species in Plasmacytoid Dendritic Cells. Redox Biology, 13, 633-645.  
&lt;br&gt;https://doi.org/10.1016/j.redox.2017.07.016</mixed-citation></ref><ref id="hanspub.35651-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">凌磊, 皮肖冰, 余旸弢, 等. 系统性红斑狼疮患者血清干扰素-α的水平变化及其临床意义[J]. 实用医学杂志, 2016, 32(1): 106-108.</mixed-citation></ref><ref id="hanspub.35651-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">Ronnblom, L. and Leonard, D. (2019) Interferon Pathway in SLE: One Key to Unlocking the Mystery of the Disease. Lupus Science &amp; Medicine, 6, e270. &lt;br&gt;https://doi.org/10.1136/lupus-2018-000270</mixed-citation></ref><ref id="hanspub.35651-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Gonzalez-Navajas, J.M., Lee, J., David, M., et al. (2012) Immunomodulatory Functions of Type I Interferons. Nature Reviews Immunology, 12, 125-135. &lt;br&gt;https://doi.org/10.1038/nri3133</mixed-citation></ref><ref id="hanspub.35651-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Dall’Era, M.C., Cardarelli, P.M., Preston, B.T., et al. (2005) Type I Interferon Correlates with Serological and Clinical Manifestations of SLE. Annals of the Rheumatic Diseases, 64, 1692-1697. &lt;br&gt;https://doi.org/10.1136/ard.2004.033753</mixed-citation></ref><ref id="hanspub.35651-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">Rother, N., Pieterse, E., Lubbers, J., et al. (2017) Acetylated Histones in Apoptotic Microparticles Drive the Formation of Neutrophil Extracellular Traps in Active Lupus Nephritis. Frontiers in Immunology, 8, 1136.  
&lt;br&gt;https://doi.org/10.3389/fimmu.2017.01136</mixed-citation></ref><ref id="hanspub.35651-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Khandpur, R., Carmona-Rivera, C., Vivekanandan-Giri, A., et al. (2013) NETs Are a Source of Citrullinated Autoantigens and Stimulate Inflammatory Responses in Rheumatoid Arthritis. Science Translational Medicine, 5, 140r-178r.  
&lt;br&gt;https://doi.org/10.1126/scitranslmed.3005580</mixed-citation></ref><ref id="hanspub.35651-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">Lande, R., Gregorio, J., Facchinetti, V., et al. (2007) Plasmacytoid Dendritic Cells Sense Self-DNA Coupled with Antimicrobial Peptide. Nature, 449, 564-569. &lt;br&gt;https://doi.org/10.1038/nature06116</mixed-citation></ref></ref-list></back></article>